Active Substances Isolated from the Secretion of Siberian Musk Deer in a Liposomal Dosage Form

Liposomal forms of preparations containing biologically active substances extracted from renewable sources of raw materials of plant and animal origin are attracting considerable research and practical interest. Liposomal drugs are efficiently absorbed in the gastrointestinal tract, retaining their structure while passing through the liver and entering the target cell. This allows either smaller amounts of the active substance to be used without losing bioavailability or its effective concentration to be increased.

Deer musk liposomes administered at doses equivalent to 300, 1500 and 3000 mg/person/day were found to exhibit an actoprotective effect, whose intensity at the minimum dose (300 mg) is comparable to that achieved at the maximum dose (3000 mg).

A course daily transpalatal administration of musk deer liposomes for 14 days was established to statistically significantly improve the indices of physical endurance and working capacity of rats in forced swimming tests under load, kineso-hydrodynamic models of swimming and rotarod performance tests. The observed increase in indicators persisted for another seven days after the cessation of administration, which indicates pharmacological cumulation. The tested drug reduces locomotor and orienting-exploratory activity, at the same time as exhibiting no adverse effect on the psycho-emotional and intoxication status of animals. In addition, no local irritant action on the route of administration was noted. The drug is assigned to toxicity class VI (relatively harmless).

1. Belousov Yu.B., Zyryanov S.K. Problema ekvivalentnosti original’nyh i vosproizvedennyh lekarstvennyh sredstv s pozicii klinicheskogo farmakologa [The problem of equivalence of original and generic drugs from the point of view of a clinical pharmacologist]. Vedomosti Nauchnogo centra ekspertizy: sredstva medicinskogo primeneniya [Bulletin of the Scientific Center for Expertise: medical products]. 2007;1:12–17. (In Russian).

2. Berezovskaya I.V. Prognoz bezopasnosti lekarstvennyh sredstv v doklinicheskih toksikologicheskih issledovaniyah [Prediction of drug safety in preclinical toxicological studies]. Toksikologicheskiy vestnik [Toxicological Bulletin]. 2010;5:17-22. (In Russian).

3. Golikov S.N., Sanotsky I.V., Tiunov L.A. Obshchie mekhanizmy toksicheskogo dejstviya [General mechanisms of toxic action]. Leningrad: Medicina Publ., 1986:280. (In Russian).

4. Guskova T.A. Toksikologiya lekarstvennyh sredstv [Toxicology of drugs]. Moscow: Russkij vrach Publ., 2003:154. (In Russian).

5. Karkischenko N.N. Al’ternativy biomeditsiny. T. 2. Klassika i al’ternativy farmakotoksikologii [Alternatives to biomedicine. Vol. 2. Classics and alternatives of pharmacotoxicology]. Moscow: VPK Publ., 2007:448. (In Russian).

6. Klinicheskaya farmakologiya [Clinical pharmacology]. Ed. by Acad. RAMS, Prof. V.G. Kukes. Moscow: GEOTAR-Media Publ., 2006:938. (In Russian).

7. Krasovskiy G.N., Rakhmanin Yu.A., Egorova N.A. Ekstrapolyaciya toksikologicheskih dannyh s zhivotnyh na cheloveka [Extrapolation of toxicological data from animals to humans]. Moscow: Medicina Publ., 2009:208. (In Russian).

8. Kukes V.G. Klinikofarmakologicheskie podhody k povysheniyu kachestva doklinicheskih i klinicheskih issledovanij novyh lekarstvennyh sredstv [Clinical and pharmacological approaches to improving the quality of preclinical and clinical studies of new drugs]. Vedomosti Nauchnogo centra ekspertizy sredstv medicinskogo primeneniya [Bulletin of the Scientific Center for Expertise of Medicinal Products]. 2006;1:7–10. (In Russian).

9. Rukovodstvo po laboratornym zhivotnym i al’ternativnym modelyam v biomedicinskih issledovaniyah [Manual on laboratory animals and alternative models in biomedical research]. Ed. by N.N. Karkischenko, et al. Moscow: Profi l’-2S Publ., 2010:358. (In Russian).

10. Frank A. Barile Clinical Toxicology. Principles, and Mechanisms. London, New York, Washington: CRC Press, 2004:441.